


Form PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 10-95) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 702-010802
		U.S. APPLICATION NO. 09/856277
INTERNATIONAL APPLICATION NO. PCT/EP99/09137	INTERNATIONAL FILING DATE 19.11.99 (19 November 1999)	PRIORITY DATES CLAIMED 19.11.98 (19 November 1998)
TITLE OF INVENTION ORAL CREATINE SUPPLEMENTATION FOR TREATING OR PREVENTING MUSCLE DISUSE SYNDROME		
APPLICANT(S) FOR DO/EO/US Peter Jozef Leo HESPEL		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made, however, the time limit for making such amendments has NOT expired d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <ul style="list-style-type: none"> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> a. WO 00/30634-Front Page with Abstract, Specification, Claims and Drawings (36 pp.) b. International Search Report (6 pp.); c. International Preliminary Examination Report (5 pp.) 		

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. PCT/EP99/09137	ATTORNEY'S DOCKET NUMBER 702-010802
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO..... \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$690.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..... \$710.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$1000.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100.00		CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	10 - 20	0	X \$18.00 \$ 0.00
Independent claims	2 - 3 =	0	X \$80.00 \$ 0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$270.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =		\$ 990.00	
Reduction of 1/2 for filing by small entity, if applicable. Small Entity status is not claimed.		\$ 0.00	
SUBTOTAL =		\$ 990.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +		\$ 0.00	
TOTAL NATIONAL FEE =		\$ 990.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$ 0.00	
TOTAL FEES ENCLOSED =		\$ 990.00	
		Amount to be: Refunded	\$
		Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ 990.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Assistant Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0650</u> . A duplicate copy of this sheet is enclosed.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: Barbara E. Johnson 700 Koppers Building 436 Seventh Avenue Pittsburgh, Pennsylvania 15219-1818 Telephone: (412) 471-8815 Facsimile: (412) 471-4094			
 SIGNATURE <u>Richard L. Byrne</u> NAME <u>28,498</u> REGISTRATION NUMBER			

PATENT APPLICATION/PCT
Atty. Docket No. 702-010802

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Peter Jozef Leo HESPEL : ORAL CREATINE
International Application : SUPPLEMENTATION FOR
No. PCT/EP99/09137 : TREATING OR PREVENTING
MUSCLE DISUSE SYNDROME

International Filing Date :
19 November 1999 :

Priority Date Claimed :
19 November 1998 :

Serial No. Not Yet Assigned :

Filed Concurrently Herewith :

Pittsburgh Pennsylvania
May 18, 2001

PRELIMINARY AMENDMENT

BOX PCT
Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified patent application as follows:

IN THE CLAIMS:

Please cancel original claims 1-8 and rewrite them as new claims 9-18 as follows:

9. A therapeutic preparation for treating or preventing muscle disuse syndrome, comprising a suitable carrier, diluent or excipient and an effective amount of one or more creatine compounds.

10. The therapeutic preparation according to claim 9, which is a drug.

11. The therapeutic preparation according to claim 9, which is a nutritional supplement.

12. The therapeutic preparation according to claim 11, which has the form of a food stuff comprising one or more additional creatine compounds.

13. A method for the prevention or treatment of muscle disuse syndrome in an animal or human for which such prevention or treatment is indicated, comprising administering a creatine compound in unit dosage form in an amount effective to treat said muscle disuse syndrome.

14. The method according to claim 13, wherein said creatine compound is creatine.

15. The method according to claim 13, wherein said creatine compound is a creatine analogue.

16. The method according to claim 13, wherein the animal or human to be treated need not in addition perform a training programme to increase muscle volume and muscle functional capacity.

17. The method according to claim 13, wherein said creatine compound in unit dosage form is administered in an amount that leads to a total daily supplementation of 0.5 to 5 g creatine.

18. The method according to claim 13, wherein said muscle disuse syndrome is the result of reduced physical activity due to immobilization, disease, aging or handicap.

IN THE ABSTRACT:

After the claims, please insert a page containing the Abstract Of The Disclosure, which is attached hereto as a separately typed page.

REMARKS

Claims 1-8 have been cancelled and rewritten as new claims 9-18 to conform the application and claims to customary United States practice.

Examination and allowance of claims 9-18 are respectfully requested.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.


By Richard L. Byrne

Richard L. Byrne
Registration No. 28,498
Attorney for Applicant
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: 412-471-8815
Facsimile: 412-471-4094

Attn: USPTO - Please do not file this document with the USPTO. It is a copy of a document filed with the USPTO. The original document is located in the file folder.

09/856277
JC18 Rec'd PCT/PTO 18 MAY 2001

ORAL CREATINE SUPPLEMENTATION FOR TREATING OR PREVENTING MUSCLE DISUSE SYNDROME

ABSTRACT OF THE DISCLOSURE

The present invention relates to the use of a creatine compound, in particular creatine or a creatine analogue, for the manufacture of a therapeutic preparation for the prevention or treatment of muscle disuse syndrome in a subject. The invention further relates to a therapeutic preparation for treating or preventing muscle disuse syndrome, comprising a suitable carrier, diluent or excipient and an effective amount of one or more creatine compounds.

ORAL CREATINE SUPPLEMENTATION FOR TREATING OR
PREVENTING MUSCLE DISUSE SYNDROME

The present invention relates to the prevention
5 and treatment of muscle disuse syndrome.

Muscle disuse syndrome is defined as the reversible deterioration of structural, functional, metabolic and neuromotor properties of skeletal muscle tissue as a result of reduced mechanical loading. The 10 degenerative symptoms typical to the muscle disuse syndrome include muscle atrophy (decreased muscle volume), reduced maximal force, reduced maximal power, increased muscle relaxation time, premature muscle fatigue, reduced muscle energy stores, reduced muscle 15 blood flow, reduced insulin sensitivity, and impaired motor control.

The muscle disuse syndrome may occur in any skeletal muscle subject to reduced mechanical loading due to whatever cause. Thus, mechanical unloading may occur 20 as a result of any disease condition, ageing, physical and/or mental handicap, forced bed rest, or any other condition associated with a reduced level of physical activity. Increased mechanical loading of the muscle, either by muscle rehabilitation training or by resumption 25 of a normal level of physical activity, reverses the muscle disuse syndrome.

One example of a condition in which muscle disuse syndrome may occur is immobilization, for example when a broken extremity like a leg or an arm is 30 immobilized in a cast for some weeks, or when a patient is forced to bed rest due to disease. The atrophy is then usually clearly visible by a slimming of the leg(s) or arm(s).

It should be noted that the muscle disuse 35 syndrome here described does not lead to the death of muscle cells. The atrophy that is found as an effect of the syndrome leads solely to a decrease in cell volume and functional capacity. However, there is no

irreversible destruction of the cells, as is the case in muscle dystrophy.

It is the object of the invention to provide a therapeutic preparation for treating or preventing muscle disuse syndrome in a subject.

According to the invention it has now been found that a relatively low dosage of one or more creatine compounds can reduce the effects of muscle disuse syndrome. Thus, by administering to a subject who is under the risk of developing or suffering from the muscle disuse syndrome, a suitable amount of one or more creatine compounds the effects of the syndrome can be reduced or even avoided, and the rehabilitation of the syndrome can be enhanced.

The use of creatine for various purposes has been described in the literature. However, neither of these disclosures are related to the actual treatment of muscle disuse syndrome or of muscles that are in principle healthy. Although the muscle atrophy to which this invention is directed are decreased in cell volume and functional capacity, they are not diseased or dying like in muscle dystrophy.

Mahanna et al. (Exp. Neurol. (1980), 68(1), 114-121) disclose the effect of β -guanidinopropionic acid (β -GPA) on skeletal muscle for evaluating the need for creatine and phosphocreatine in the maintenance of muscle fiber size. However, β -GPA not only leads to muscle creatine depletion, but also the ATP concentration in the muscles studied is markedly reduced. Conversely, in healthy muscle cells ATP concentration is normal, even during the most severe conditions of disuse. The decrease of muscle ATP content upon β -GPA administration is a typical symptom of the toxic effects of β -GPA on muscle, that in turn cause muscular adaptations that are markedly different from the normal physiological adaptations of skeletal muscles to mechanical loading (training) and unloading (disuse), or creatine administration. In fact, animal studies using β -GPA administration may possibly

serve as an experimental model of very severe conditions of pathologic muscle dystrophy, but not of the symptoms of the muscle disuse syndrome as described herein. The toxic effects of GPA, indeed, induce cellular adaptations 5 that to a large degree are different from the reversible physiological muscular adaptations during the muscle disuse syndrome (Laskowski B et al., Metabolism 30, 1080-1085, 1981; Moerland TS et al., American Journal of Physiology 257, C810-C816, 1989; De Saedeleer M & 10 Marechal G, Pflügers Archives European Journal of Physiology 402, 185-189, 1984; Levine S et al, American Journal of Physiology 271, C1480-C1486, 1996). In fact, GPA-treatment is used as a model for muscle dystrophy. Results obtained with diseased muscle cells are not 15 indicative for healthy muscle cells.

Wyss et al. (Medical Hypotheses (1998), 51(4), 333-336) is also concerned with oral creatine supplementation in muscle disease, such as Duchenne muscle dystrophy, for alleviating the clinical symptoms.

20 WO98/00148 relates to drug preparations that contain creatine and at least one calcium, magnesium, manganese or zinc salt to reduce the creatine dose.

Oral creatine supplementation of healthy individuals, in particular athletes, has been shown to 25 improve performance during short maximal exercise bouts. Although long-term creatine supplementation has rapidly developed as a standard ergogenic practice in athletes, there was initially no scientific evidence that this practice could be in fact beneficial. It has been 30 suggested that the observed increase of fat free mass occurring as a result of creatine supplementation was solely due to body water accumulation and not to muscle hypertrophy.

The use of creatine according to the invention 35 for the treatment of muscle disuse syndrome, which in principle involves healthy muscles that have a decreased cell volume and functional capacity, but are in fact

still intact, cannot be derived from these prior art documents.

The treatment of the invention can be a preventive treatment when the therapeutic preparation is 5 administered to the subject from the onset of the risk to develop the syndrome. Also, the preparation can be given to patients already suffering from the syndrome.

For the effective treatment or prevention of muscle disuse syndrome, the creatine compound is to be 10 administered on a daily basis, or on an intermittent basis in a total daily amount of between 0.5 and 10 g, preferably between 1 and 5 g, such as about 2.5 g, per day. This amount can also be given in more than one portion over the day. The one or more creatine compounds 15 can be combined with suitable excipients, diluents, carriers etc. to obtain a dosage form for administration. Suitable dosage forms are drinks, tablets, capsules, powders, sweets or any nutritional supplement or nutrient containing added creatine.

20 Surprisingly, it has further been found that the administration of one or more creatine compounds can lead to improved glucose tolerance, an increased insulin sensitivity of the muscle, an increase in muscle capillarisation and an enhanced muscle relaxation. The 25 latter not only reduces relaxation-dependent energy consumption in muscles during exercise, but at the same time may conceivably improve muscle coordination by reducing the amount of co-contraction activity between agonist and antagonist muscles.

30 This led the inventors to the additional finding that creatine treatment can also be used to treat muscle disuse syndrome in elderly. Elderly have a reduced mechanical loading due to the fact that they are not as mobile as younger people. Therefore, the muscle disuse 35 syndrome is intrinsic to aging.

Muscle disuse syndrome may also be caused by chronic fatigue syndrome. Creatine supplementation of the invention can also be used to treat the muscle disuse

syndrome that is the result of the chronic fatigue syndrome.

The term "therapeutical preparation" is used in this application to encompass both preparations for 5 treatment, i.e. drugs, and nutritional supplements for example in the form of food stuffs in liquid or solid form that contain additional creatine. The therapeutical preparation may be used alone or in combination with a physical rehabilitation programme. The latter is, 10 however, not essential for obtaining the desired effect.

The present invention will be further illustrated in the examples that follow. In the examples reference is made to the following figures:

Figure 1: Effect of oral creatine intake on m. quadriceps cross-sectional area during immobilization and rehabilitation. Values are mean \pm S.E.M. of 10 observations and represent the change of muscle cross-sectional area (CSA) compared with baseline value, which was set equal to zero. S.E.M.'s of some data points are 15 omitted for clarity of the figure. A cast first immobilized the right leg (□, ■) during a period of 2 weeks, while the other leg served as a control leg (○, ●). Thereafter subjects participated in a 10 weeks rehabilitation program for the knee extensors of the 20 immobilized leg. Subjects ingested either supplementary creatine monohydrate (filled symbols) or placebo (open symbols). * Refers to a significant treatment-effect 25 compared with placebo value in the corresponding leg, $p<0.05$.

Figure 2: Effect of oral creatine intake on maximal isometric knee-extension torque during immobilization and rehabilitation. Values are mean \pm S.E.M. of 10 observations and represent the change of maximal isometric knee-extension torque compared with 30 baseline value which was set equal to zero. S.E.M.'s of some data points are omitted for clarity of the figure. A cast first immobilized the right leg (□, ■) during a period of 2 weeks, while the other leg served as a 35

control leg (O,●). Thereafter subjects participated in a 10 weeks rehabilitation program for the knee extensors of the immobilized leg. Subjects ingested either supplementary creatine monohydrate (filled symbols) or 5 placebo (open symbols). * Refers to a significant treatment-effect compared with placebo, P<0.05.

Figure 3: Effect of oral creatine intake on power output during a bout of maximal dynamic knee-extension exercise during immobilization and 10 rehabilitation. Values are mean \pm S.E.M. of 10 observations and represent the change of mean power production during a series of 30 maximal dynamic knee-extensions, compared with baseline value which was set equal to zero. S.E.M.'s of some data points are omitted 15 for clarity of the figure. A cast first immobilized the right leg (O,●) during a period of 2 weeks, while the other leg served as a control leg (O,●). Thereafter subjects participated in a 10 weeks rehabilitation program for the knee extensors of the immobilized leg. 20 Subjects ingested either supplementary creatine monohydrate (filled symbols) or placebo (open symbols). * Refers to a significant treatment-effect compared with placebo, P<0.05.

Figure 4: Effect of oral creatine intake on relaxation time of quadriceps and hamstring muscles during immobilization and rehabilitation. Values are mean \pm S.E.M. of 10 observations and represent the time for muscles to relax from 75% to 25% of the maximal isometric torque. A cast first immobilized the right leg during a 25 period of 2 weeks, while the other leg served as a control leg. Thereafter subjects participated in a 10 weeks rehabilitation program for the knee extensors of the immobilized leg. Subjects ingested either supplementary creatine monohydrate (filled symbols) or 30 placebo (open symbols). Muscle relaxation time was measured in milliseconds (ms) in both hamstring and quadriceps muscles, following a maximal isometric contraction of the respective muscles. The time points on 35

the x-axis refer to baseline measurements before immobilization (times 1, 6, 11, 16), after immobilization (times 2, 7, 12, 17), after 3 weeks of rehabilitation (times 3, 8, 13, 18) and after 10 weeks of rehabilitation (times 4, 9, 14, 19) for the right and left m. quadriceps and for the right and left hamstrings, respectively. & refers to a significant treatment effect compared with placebo, $p<0.05$.

Figure 5: Effect of oral creatine

supplementation on muscle fibre cross-sectional areas during leg immobilization and rehabilitation. Values are mean \pm S.E.M. of 8 observations and represent cross-sectional areas of type I, type IIa and type IIb muscle fibers, respectively. A cast first immobilized the right leg during a period of 2 weeks. Thereafter subjects participated in a 10 weeks rehabilitation program for the knee-extensors of the immobilized leg. Subjects ingested either supplementary creatine monohydrate (filled bars) or placebo (open bars). Muscle fibers were visualized on transversal microsections of needle biopsy samples of m. vastus lateralis by myofibrillar ATPase staining.

* Refers to a significant time-effect compared with the post-immobilization value, $p<0.05$.

Figure 6: Effect of long-term creatine intake

on muscle glycogen during immobilization and rehabilitation. Values are means \pm S.E.M. ($n = 8$). Before and after two weeks of immobilization and after 3 and 10 weeks of rehabilitation of the right leg a muscle biopsy was taken from the vastus lateralis. During immobilization and rehabilitation subjects ingested creatine monohydrate (closed symbols) or placebo (open symbols). Muscle glycogen was determined by standard enzymatic spectrophotometrical assays. * $p<0.05$ compared with placebo values.

Figure 7: Effect of long-term creatine intake
on muscle fiber capillarization during immobilization and rehabilitation. Values are means \pm S.E.M. ($n = 6$). Before and after two weeks of immobilization and after 3 and 10

weeks of rehabilitation of the right leg a muscle biopsy was taken from the vastus lateralis. During immobilization and rehabilitation subjects ingested creatine monohydrate (closed symbols) or placebo (open symbols). Muscle capillaries in type I (panel A), type IIa (panel B) and type IIb (panel C) muscle fibers were visualized by PAS analyses.

Figure 8: Effect of acute and long-term creatine intake on the response of blood glucose concentration to oral glucose intake. Values are means \pm S.E.M. (n = 8-9). Subjects ingested 1g glucose \cdot kg $^{-1}$ BW at time t_0 after 12 weeks (panel B) of either oral creatine supplementation (closed symbols) or placebo (open symbols), and 10 weeks following cessation of the creatine or placebo intake (panel A). Thirty min prior to the glucose administration (t_{-30}), subjects ingested 10g of creatine monohydrate or placebo. Blood glucose concentration was measured by 15 min intervals on capillary blood samples. * p<0.05 compared with the corresponding placebo value.

EXAMPLES

EXAMPLE 1

Use of creatine for the treatment of disuse atrophy

1. Materials and Methods

1.1 Subjects

Twenty-two healthy subjects, 12 males and 7 females, ranging in age from 20 to 23 years gave their informed written consent to take part in the study. They were informed in detail of all experimental procedures to be undertaken and were asked to abstain from any medication during the period of the study and to avoid changes in their diet or level of physical activity. Three of the female subjects were taking oral contraceptive medication.

1.2 Study Protocol

A double-blind study was performed over a 12-week period. During the first week of the study, baseline measurements were performed (Session 1, Week 0). On day 5 1, and after a light standardized meal (600 kcal, 60% carbohydrates, 25% fat, 15% proteins) m. quadriceps cross-sectional area (CSA) was measured by Magnetic Resonance Imaging (MRI) after which a percutaneous needle biopsy of the right m. vastus lateralis was taken for 10 biochemical and histochemical analyses. On day 4, and again after a light standardized meal, isometric and dynamic maximal knee-extension torque of the right and left leg was evaluated using an isokinetic dynamometer. Subsequently, subjects were assigned to either a creatine 15 (CR: n = 11) or a placebo (P: n = 11) group enabling two groups of similar sex and m. quadriceps cross-sectional area to be obtained. From the next day CR subjects ingested 5g of creatine monohydrate 4 times per day. The creatine supplements were flavored by the addition of 20 citrate (60mg·g⁻¹ creatine) and maltodextrine (940mg·g⁻¹ creatine), while the P group ingested only maltodextrine containing citrate (40mg·g⁻¹ maltodextrine). Creatine and placebo powders were identical in taste and appearance. Furthermore, subjects were instructed to dissolve the 25 supplements in hot water within 1 min before ingestion. The subject's right leg was then immobilized at a knee angle of ~160° by a light polyester cast, reaching from groin to ankle. Subjects received crutches and permanent free access to private transportation services in order 30 to limit loading of the immobilized leg during the immobilization period. A week later the cast was removed and the knee-joint was passively mobilized for 20 min, after which subjects were allowed to take a shower. Immediately after, a new cast was fitted for another week 35 of immobilization.

At the end of the second week of right leg immobilization the cast was removed and post-immobilization measurements were performed (Session 2,

Week 2). Session 2 was identical to session 1, with the exception that on the 1st to 3rd day following removal of the cast subjects participated in a 30 min physiotherapy session (passive mobilization), aimed at restoring normal 5 knee-joint mobility before the assessment of maximal knee extension torque was made on day 4.

Immediately after session 2, a 10-week rehabilitation program was started. Subjects participated in a unilateral training program for the right leg, at a 10 rate of 3 sessions per week. Each training session consisted of 4 series of 12 unilateral knee-extensions ranging from a 90° knee-angle to full extension at a rate of 60°· sec⁻¹, interspersed by 2 min rest intervals, on a knee-extension apparatus (Technogym®). The workload was 15 set at 60% of maximum isometric knee-extension torque, which was measured at a 90° knee-angle at the start of each session using a calibrated force transducer. During the last 7 weeks of the training period, a series of 6 instead of 4 unilateral knee-extensions were performed. 20 All training sessions were supervised by one of the investigators. The dose of CR or P ingested was reduced from 4 times 5g per day during immobilization to 3 times 5g per day during the initial 3 weeks of rehabilitation, and thereafter to a single 5g daily.

25 After 3 (Session 3, Week 5) and 10 (Session 4, Week 12) weeks of rehabilitation, and at least 48 hours following the last training session, subjects returned to the laboratory for an intermediate and a post-training evaluation session, respectively. All measurements over 30 the course of sessions 1 to 4 were done on the same day of the week and at the same time of the day for each subject. The results of the measurements were disclosed neither to the subjects nor to the investigators until completion of the study. Determination of m. quadriceps 35 cross-sectional area (CSA)

N.M.R. imaging was performed in a 1.5 T scanner (Vision, Siemens) using a phased array body coil positioned over the upper legs. Subjects lay in supine

position with a plastic leg mould fitted, allowing accurate and reproducible positioning of the subject's legs with reference to the coil and magnet during different MRI sessions. T1 weighted images were acquired 5 with a spin-echo sequence (TR/TE=500/12 ms). First, the most distal point of the medial condylus of the femur was located by frontal scanning. Thereafter, three axial slices with 10 mm thickness and 30 mm spacing, were positioned on coronal slices at 17, 20 and 23 cm proximal 10 to the reference point. The in-plane resolution of the axial images was 1.12 x 0.78 mm. Images were transferred to a dedicated workstation for quantitative processing. CSA of m. quadriceps was determined by digitisation of the images using Visual Basic software (Microsoft Co., 15 USA). Digitisation was done in duplicate by two independent investigators, after which values were averaged. However, if either intra-observer or inter-observer differences for a given image exceeded 5%, the investigators re-digitised the image. For each single 20 image, CSA was eventually calculated as the mean of the values obtained by the two investigators. Finally, quadriceps CSA (cm^2) was defined as the mean of the 3 axial scan images taken at 17, 20 and 23 cm proximal to the medial condylus of the femur, respectively.

25 Determination of knee-extension torque

Maximal voluntary torque and fatigue, and relaxation time of the knee-extensors was evaluated on a self-constructed isokinetic dynamometer that was calibrated prior to each experiment. The dynamometer 30 consisted of a computer controlled asynchronous electromotor (AMK Dynasyn, 19kW), instrumented with a torque transducer (Lebow, maximal torque 565 Nm, 0.05% precision). Prior to the study, subjects reported twice to the laboratory to be familiarized with the test 35 procedure. The exercise test consisted of unilateral knee-extensions performed in a sitting position on the dynamometer. After a 5-min standardized warm-up, the subjects performed 3 voluntary maximal isometric

contractions (3 s), interspersed by 2-min rest intervals, at a knee-angle of 110°. Maximal isometric torque (Nm), and relaxation time (msec) was then obtained from the smoothed curve of the static torque. Relaxation time was 5 defined as the time of torque decay from 75% to 25% of the maximal isometric torque. On the next day, and again after a standardized 5-min warm-up, subjects performed a bout of 30 dynamic maximal voluntary knee-extensions at a constant velocity of 180°·sec⁻¹, starting from 90° to full 10 extension (180°). After each contraction, the leg was returned (180°·sec⁻¹) passively to the starting position from which the next contraction was immediately 15 initiated. Torque and angular velocity were measured during each contraction and were simultaneously digitised (250 Hz) by an on-line computer. Finally, power was calculated from the registered torque and velocity measurements.

1.3 Muscle biochemistry and histochemistry

20 Muscle samples were obtained from the m. vastus lateralis of the right leg, using the needle biopsy technique (Bergström, J. Scandinavian Journal of Clinical and Laboratory Investigation 14 (suppl. 68), 1-110. 1962) with suction being applied. Incisions were made through 25 the skin and muscle fascia following the administration of local anaesthesia (2-3 ml of 1% lidocaine). During sessions 2, 3 and 4, the incision was made either proximal or distal to the incision made at an earlier session. Following removal from the limb, a piece of each 30 muscle biopsy was immediately freed from blood and visible connective tissue, rapidly frozen in liquid nitrogen, and stored at -80°C for subsequent biochemical analysis. The remaining muscle was mounted in embedding medium, frozen in isopentane, cooled to its freezing point in liquid nitrogen, and stored at -80°C until 35 analyses were performed at a later date. For muscle substrate and enzyme assays muscle samples were freeze-dried and washed twice in petroleum ether to remove fat.

Thereafter, a portion of each sample was dissected free of visible blood and connective tissue and was pulverized. Part of the powdered extract (3-5 mg) was then used for spectrophotometric determination of ATP, 5 PCr and free Cr concentrations (Harris, R. et al., Scandinavian Journal of Clinical and Laboratory Investigation 33, 109-120. 1974). Muscle total creatine concentration was calculated as the sum of PCr and free Cr concentrations. For the histochemical analyses, serial 10 transverse sections (10 μ m) were cut from the biopsies with a microtome at -20°C and stained for myofibrillar ATPase to identify fibre types (Brooke, M.H. and Kaiser, K.K. Journal of Histochemistry and Cytochemistry 18, 670-672. 1970).

15

1.4 Statistical analysis

All data are expressed as mean \pm S.E.M. Statistical evaluation (Statistica® software, Ohio, USA) of the data was performed using repeated measures 2-way 20 analysis of variance, using Tukey's test for post-hoc multiple comparisons where appropriate. The relationship between variables was calculated by Pearson's correlation coefficient. The level of statistical significance was set at $p<0.05$.

25

2. Results

2.1 Body mass and treatment identification

At the start of the study body mass was 66.9 \pm 2.7 kg in P versus 65.9 \pm 3.1 kg in CR. Over the course 30 of the study, body mass increased ($p<0.05$) in both groups, but there was no significant difference between P and CR at any time during the study. Body mass in P was 68.2 \pm 2.8, 68.1 \pm 2.8 and 68.4 \pm 3.0 kg immediately after immobilization and after 3 and 10 weeks of 35 rehabilitation, respectively. Corresponding values in CR were 66.7 \pm 3.2, 67.3 \pm 3.2 and 68.4 \pm 3.3 kg. The training workload during rehabilitation was similar for

the 2 groups over the entire rehabilitation period. Initial knee-extension 1RM was 67 ± 9 kg in P versus 70 ± 8 kg in CR, and increased to 103 ± 10 kg and 98 ± 10 , respectively, during the final stage of the 5 rehabilitation period. At the end of the study subjects were asked whether they had any notion of the treatment they had received but, irrespective of the supplement received, all were unsure. No side effects were reported during the entire duration of the study.

10

2.2 Muscle cross-sectional area

2.2.1 Immobilized leg

At baseline, m. quadriceps cross-sectional area (CSA) was $90 \pm 5 \text{ cm}^2$ in P versus $92 \pm 5 \text{ cm}^2$ in CR. As 15 shown in Figure 1, 2 weeks of immobilization decreased m. quadriceps CSA by ~10% ($p<0.05$, range: 0-15%) to 81 ± 4 in P and $82 \pm 5 \text{ cm}^2$ in CR. During subsequent rehabilitation, m. quadriceps CSA increased at a faster rate in CR than in P ($p<0.05$). Compared with post- 20 immobilization, after 3 and 10 weeks of rehabilitation in CR m. quadriceps CSA increased by 15% (range: 9-19%) and 21% (range: 20-26%), respectively. However, in P, the corresponding increases amounted to only 9% and 14%. Thus, compared with pre-immobilization baseline values, 25 at the end of the 10-week rehabilitation period the right m. quadriceps CSA was greater ($p<0.05$) in CR ($100 \pm 6 \text{ cm}^2$) but not in P ($93 \pm 4 \text{ cm}^2$).

2.2.2 Control leg

30 At the start of the study quadriceps CSA was $91 \pm 4 \text{ cm}^2$ in P and was similar in CR ($93 \pm 5 \text{ cm}^2$). In P, m. quadriceps CSA did not significantly change throughout the study (Figure 1). Conversely, in CR m. quadriceps CSA progressively increased to a value that was higher 35 ($p<0.05$) than at baseline at week 12 ($100 \pm 6 \text{ cm}^2$).

2.3 Muscle strength

2.3.1 Immobilized leg

At the start of the study, maximal isometric knee-extension torque was 151 ± 12 in P and 141 ± 10 Nm in CR. As shown in Figure 2, immobilization decreased torque to the same degree (~27%, range: 0-31%) in both groups (-34 ± 6 Nm in P Vs -28 ± 5 Nm in CR). However, during subsequent rehabilitation, torque increased at a faster rate in CR than in P ($p<0.05$). In CR, after 3 and 10 weeks of leg extension training, maximal isometric torque was increased by 38% (range: 16-56%) and 50% (range: 15-65%), respectively. Corresponding increments in P amounted to 32% (range: 20-40%) and 42% (range: 24-52%). Thus, compared with the pre-immobilization 15 baseline, at the end of the rehabilitation period muscle torque had increased ($p<0.05$) by 10% and 20% in P and CR, respectively. Mean power production during 30 maximal dynamic knee-extensions at baseline was 152 ± 16 watt in CR versus 160 ± 15 watt in P (n.s., see Figure 3). 20 Immobilization decreased ($p<0.05$) power to the same degree (~25%) in both groups (CR, 113 ± 12 watt, P, 122 ± 12 watt). However, during rehabilitation, power output increased at a faster rate in CR than in P ($p<0.05$). Compared with the pre-immobilization baseline, at the end 25 of the 10-week rehabilitation period the mean power production during the bout of maximal dynamic knee-extensions tended to be higher (+13%, n.s.) in CR (172 ± 16 watt) and similar in P (165 ± 17 watt).

30 2.3.2 Control leg

Maximal isometric knee-extension torque of the control leg was unchanged in both groups during immobilization (Figure 2), but increased during rehabilitation ($p<0.05$). Maximal torque also increased 35 more ($p<0.05$) in CR than in P during the rehabilitation period. Thus, after 12 weeks of creatine supplementation, maximal torque (159 ± 12 Nm) was on average 10% higher in CR than in P ($p<0.05$). Power production during the

dynamic knee-extension exercise was 144 ± 14 watt and 153 ± 15 watt at baseline in CR and P, respectively (Figure 3). In P, power was stable around ~155 watt throughout the study, whereas in CR it progressively increased 5 ($+14\%$, $p<0.05$) to peak at 163 ± 16 watt at the end of the 12-week creatine supplementation period.

2.4 Muscle relaxation time

Relaxation time was measured in quadriceps and 10 hamstring muscles of both the immobilized leg (right leg) and the control leg (left leg) following maximal isometric contraction. As shown in Figure 4, at baseline relaxation times were on the average ~75-80 msec for the m. quadriceps and ~80-90 msec for hamstrings in both P and 15 CR. During P muscle relaxation time did not significantly change over the 12-week treatment period, either in the right leg during immobilization and rehabilitation, or in the left leg. Conversely, creatine administration caused muscle relaxation times to significantly decrease. Thus, 20 whilst muscle relaxation time tended to increase in P during immobilization in both quadriceps and hamstring muscle (n.s.), it decreased ($p<0.05$) in CR. Accordingly, after 3 and 10 weeks of rehabilitation relaxation times were markedly lower ($p<0.05$) in CR than in P, both in the 25 right and in the left leg and in both the quadriceps muscle and the hamstrings.

2.5 Muscle histochemistry

Due to the labor intensive nature of the 30 analysis, histochemical measurement of biopsy material of only the immobilized leg was performed in a subgroup of 16 subjects. At baseline, absolute muscle fibre cross sectional area (CSA_f ; see Figure 5) in type I, type IIa and type IIb fibers was not significantly different 35 between groups. During immobilization CSA_f did not change significantly in any fibre type in P or CR. Compared with post-immobilization values, during the 10-week rehabilitation period CSA_f in P increased ($p<0.05$) on the

average by 20%, 30% and 37% in type I, type IIa, and type IIb fibers, respectively. Corresponding increments were, on average, greater in CR (I +37%; IIa +59%; IIb +56%). However, due to large data variability, in conjunction 5 with the small number of observations, a statistically significant difference between groups was not achieved. In type I fibers, CSA_f expressed relative to total CSA (%CSA_f), from baseline to the end of the rehabilitation period decreased ($p<0.05$) from $60\pm 5\%$ to $53\pm 5\%$ in P (n.s.) 10 and from $53\pm 3\%$ to $43\pm 4\%$ in CR. Type IIa %CSA_f concomitantly increased ($p<0.05$) from $29\pm 3\%$ to $39\pm 5\%$ in CR. Corresponding values in P were $28\pm 4\%$ and $34\pm 3\%$ (n.s.). Type IIb %CSA_f was stable throughout the study at ~13% in P versus ~17% in CR.

15

2.6 Muscle biochemistry

Muscle phosphocreatine (PCr) concentration at baseline was not significantly different between the 2 groups (table 1). During immobilization, PCr 20 concentration decreased ($p<0.05$) to about 15% below baseline in P. This fall was completely prevented by creatine supplementation ($p<0.05$). In P, the muscle PCr concentration returned to pre-immobilization baseline value within the initial 3 weeks of rehabilitation, after 25 which the level was maintained. Conversely, in CR, the muscle PCr concentration increased ($p<0.05$) to ~12% above the baseline value after 3 weeks of rehabilitation. However, this PCr "overshoot" was reversed during the final stage of the rehabilitation period.

30

The muscle free creatine concentration was similar in P and CR throughout the study. However, compared with the pre-immobilization baseline value, muscle free creatine concentrations were higher after both immobilization and rehabilitation ($p<0.05$). Muscle 35 total creatine concentration at baseline was similar in P and CR. In P, immobilization did not change total creatine level. However after 3 weeks but not 10 weeks of rehabilitation it was slightly increased ($p<0.05$).

Conversely in CR, muscle total creatine was higher after immobilization period and following the initial 3 weeks of knee-extension training compared with P. However, together with the declining muscle PCr (table 1), muscle 5 total creatine concentration had returned to the baseline value by the end of the rehabilitation schedule. Muscle ATP concentration ranged from 17.5 ± 0.6 to 21.5 ± 0.5 mmol·kg⁻¹ D.W. and was not significantly affected by immobilization or rehabilitation in either experimental 10 group.

Table 1

	Immobilization		Rehabilitation	
	pre	post	3 weeks	10 weeks
15	Free creatine			
	Placebo	31.3 ± 3.3	$41.3 \pm 3.6^*$	$43.5 \pm 5.4^*$
	Creatine	30.6 ± 2.9	$48.5 \pm 4.5^*$	$53.9 \pm 5.4^*$
20	Phosphocreatine			
	Placebo	76.5 ± 1.8	$64.9 \pm 3.1^{†*}$	73.8 ± 2.6
	Creatine	82.4 ± 6.2	80.2 ± 5.8	$89.7 \pm 6.8^*$
	Total creatine			
	Placebo	108.8 ± 2.8	106.2 ± 5.7	$117.3 \pm 5.1^*$
	Creatine	113.9 ± 8.4	$128.7 \pm 11.6^*$	$143.6 \pm 11.6^*$

25 Values are mean \pm S.E.M. of 8 observations and represent concentrations ($\mu\text{mol.g}^{-1}$ DW) measured in needle biopsy samples obtained from *m.vastus lateralis*. Total creatine concentration was calculated as the sum of free creatine and phosphocreatine concentrations measured. A cast first immobilised the right leg during a period of 2 weeks. Thereafter subjects participated in a 10-week rehabilitation program for the knee-extensors of the immobilised leg. Subjects ingested either 30 supplementary creatine monohydrate or placebo. See METHODS for further details.

* refers to a significant treatment-effect compared with placebo, $p < 0.05$. † refers to a significant time-effect compared with the pre-immobilisation value, $p < 0.05$.

EXAMPLE 2

Effect of oral creatine supplementation on muscle glycogen and glucose tolerance during immobilization and rehabilitation

5

1. Methods

1.1 Subjects

Eight male (21.7 ± 0.3 yr, 71.5 ± 2.9 kg) and nine female (21.7 ± 0.4 yr, 64.8 ± 1.8 kg) healthy volunteers participated in the study. They gave written consent after having been informed in detail of all the experimental procedures to be undertaken. Subjects were instructed to abstain from any medication and to avoid changes in their usual physical activity level and other living habits during the period of the study. Three of the female subjects were taking oral contraceptives throughout the study. The local ethics committee approved the study protocol.

20 1.2 Study protocol

At the start of the study 22 subjects were assigned to either a creatine (N=11; CR) or a placebo group (N=11; P) so as to obtain 2 groups of similar distribution for body weight and gender. After baseline measurements, a cast immobilized the subjects' right leg for 2 weeks, where after they underwent a standardized 10-week resistance-training program. The training consisted of 4 to 6 series of 12 unilateral knee-extensions at a workload of 60% of 1RM and at a rate of 3 training sessions per week. During immobilization the CR group received 5g of creatine monohydrate, 4 times per day, while the P group received placebo supplements (5g maltodextrine 4 times per day). During the training period, the creatine/placebo supplements were reduced to 5g 3 times per day from week 1 to 3, and further to a single 5g daily intake from week 4 to 10. The subjects were instructed to dissolve the creatine powders in hot

water immediately before ingestion. The placebo and the creatine supplements were flavored by the addition of citrate and maltodextrine to be identical in appearance and taste. Before (PRE) and after (POST) two weeks of 5 immobilization, and after 3 (R3) and 10 (R10) weeks of rehabilitation a percutaneous needle biopsy of the right vastus lateralis muscle by using the needle biopsy technique with suction being applied. Incisions were made through the skin and muscle fascia under local anesthetic 10 (2-3 ml of 1% lidocaine). During sessions 2, 3 and 4 the incision was made either proximal or lateral to the incision made at an earlier session. A piece of each muscle biopsy was immediately blotted and cleaned from visible connective tissue, rapidly frozen in liquid 15 nitrogen, and stored at -80°C for subsequent biochemical analyses. The remaining muscle was mounted in embedding medium, frozen in isopentane, cooled to its freezing point in liquid nitrogen, and stored at -80°C until histochemically analyzed at a later date.

20

1.3 Oral glucose tolerance test

Seventeen (CR = 9; P = 8) subjects participated in an oral glucose tolerance test. At the end of the 10-week rehabilitation period, and at least 48 hours 25 following the last training session, the subjects reported to the laboratory in the morning, after an overnight fast. Subjects were seated in a comfortable chair and remained in the seated position during the entire experiment. After 15 min of rest a 75 μ l capillary 30 blood sample from the hyperemic (Finalgon \circledR) earlobe into Na-heparinized glass capillaries, and a 10ml blood sample from an antecubital vein into Na-heparinized tubes (Vacutainer \circledR), were taken. Immediately after (t_{-30}) subjects from the CR group ingested 10g of creatine 35 monohydrate which was dissolved in 150 ml of warm tea, whereas P subjects received the tea only. Thirty min later (t_0) a second capillary blood sample was taken, whereupon the subjects ingested 1g of glucose \cdot kg $^{-1}$ BW,

which was dissolved in 300ml of water. Thereafter, additional capillary blood samples were taken at 15 min intervals (t_{15} , t_{30} , t_{45} , t_{60}). In addition at t_{30} another 10ml blood sample was taken from an antecubital vein.

5 Throughout this example data obtained during this experimental session are referred to as the "creatine loaded condition".

After this glucose tolerance test creatine and placebo supplementation was stopped for 10 weeks. Such 10 time period previously has been demonstrated to be largely sufficient to establish a complete wash out of "extra" muscle creatine stores following long-term creatine intake. Thereafter subjects reported back to the laboratory on the same day of the week and time of the 15 day, and underwent an identical oral glucose tolerance test.

1.4 Biochemical and histochemical analyses

Muscle samples for biochemical determinations 20 were first freeze-dried and washed twice in petroleum ether to remove fat. Thereafter a portion of each sample was dissected free of visible blood and connective tissue and was pulverized. The powdered extract was then used for spectrophotometric determination of glycogen, free 25 creatine and phosphocreatine concentration (Harris, R.C. et al., Scand. J. Clin. Lab. Invest. 33: 109-120, 1974).

For the histochemical measurements, serial transverse sections (10 μ m) were cut with a microtome at -20°C and stained for myofibrillar ATPase to identify 30 fiber types (Brooke, M.H. and K.K. Kaiser, Journal of Histochemistry and Cytochemistry 18: 670-672, 1970) and with the amylase-periodic acid-Schiff reagent (PAS) method to visualize capillaries (Andersen, P. Acta. Physiol. Scand. 95: 203-205, 1975). Fiber area and 35 capillary density were calculated (Andersen, P. and J. Henriksson, J. Physiol. 270: 677-691, 1977).

Capillary blood samples were immediately analyzed for glucose concentration using an automated glucose analyzer (Y.S.I. glucose analyzer, model 2300 STAT). Thereafter, plasma was separated immediately by 5 high-speed centrifugation and was stored at -80°C until assayed for creatine and insulin concentration.

Plasma creatine was measured using a standard enzymatic fluorometric assay (Bergmeyer, H.U. Methods of Enzymatic Analysis. Weinheim: VCH Verlagsgesellschaft, 10 1985).

Insulin was determined by a double-antibody radioimmunoassay with rat insulin as the standard (Novo Research Institute, Bagsvaerd, Denmark).

15 1.5 Data analysis

Muscle total creatine concentration was calculated as the sum of free creatine and phosphocreatine. Capillary diffusional index was calculated by dividing mean muscle fiber area by the 20 number of capillaries per fiber type. Blood glucose disposal was defined as the area under the Δ blood-glucose curve (see Figure 8) between 0 and 60 min after glucose ingestion. The glucose area (GA) was calculated according to the trapezoidal rule. All data are given as mean \pm 25 SEM.

Differences between experimental groups were statistically evaluated by a repeated measures two-way-analysis of variance using Statistica® software (Statsoft Inc., Tulsa, USA). A probability level of $p < 0.05$ was set 30 as the criterion for statistical significance.

2. Results

2.1 Muscle glycogen

Initial muscle glycogen concentration was $407 \pm$ 35 $43 \mu\text{mol} \cdot \text{g}^{-1}$ DW in controls versus $379 \pm 19 \mu\text{mol} \cdot \text{g}^{-1}$ DW in the creatine group. As shown in Figure 6 muscle glycogen did not significantly change during immobilization in

either group. During the initial 3 weeks of rehabilitation muscle glycogen increased ($p<0.05$) in both groups. However, the increase was greater in CR than in P. Hence after 3 weeks of rehabilitation training, muscle glycogen concentration was higher ($p<0.05$) in CR ($660 \pm 70 \text{ mmol} \cdot \text{kg}^{-1} \text{ DW}$) than in P ($520 \pm 60 \text{ mmol} \cdot \text{kg}^{-1} \text{ DW}$). However, during the last 7 weeks of the rehabilitation period, muscle glycogen dropped back to the similar baseline values in both groups.

10

2.2 Histochemistry

In the total group of subjects at baseline the degree of capillarization was highest in type I and type IIa fibers (5.0 ± 0.2 capillaries/fiber in type I vs. 5.1 ± 0.2 in type IIa), and was lower ($p<0.05$) in type IIb fibers (4.4 ± 0.3). However, compared with P (I: 5.4 ± 0.2 ; IIa: 5.5 ± 0.2 ; IIb: 4.7 ± 0.3), the number of capillaries in IIa fibers, but not in type I and IIb fibers, was significantly lower ($p<0.05$) in CR (I: 4.5 ± 0.2 ; IIa: 4.6 ± 0.3 ; IIb: 3.9 ± 0.4 ; see Figure 7). The number of capillaries significantly changed in any fiber type during neither immobilization nor during the initial 3 weeks of the rehabilitation period. However, between 3 and 10 weeks of rehabilitation, the number of capillaries increased in CR in type I (n.s.), type IIa ($p=0.09$) and type IIb fibers ($p<0.05$), whilst it was unchanged in P. Thus, at the end of the study, in CR the number of capillaries of all fiber types was ~20-25% higher than at baseline.

30

Diffusional area indices (DI) at baseline were 10-15% higher in CR than in P. Neither the immobilization, nor the initial 3 weeks of rehabilitation significantly changed DI. However, compared with post-immobilization values, 10 weeks of rehabilitation in P increased (n.s.) DI by about 30% in all fiber types. Conversely, in CR only DI for type IIb fibers increased (+15%, n.s.) during rehabilitation, whilst DI for type I and IIa fibers was unaffected.

2.3 Glucose tolerance test

2.3.1 Plasma creatine.

Plasma creatine concentration in P was constant at $45-80 \mu\text{mol}\cdot\text{l}^{-1}$ throughout the glucose tolerance test, 5 both at baseline and after 12 weeks of placebo intake (table 2). In CR, baseline plasma creatine concentration was $62 \pm 20 \mu\text{mol}\cdot\text{l}^{-1}$ at t_{-30} , and increased ($p<0.05$) to $1.40 \pm 0.18 \text{ mmol}\cdot\text{l}^{-1}$ by 1 hour (t_{30}) after the creatine intake. Corresponding values after 12 weeks of oral creatine 10 supplementation were 111 ± 18 at t_{-30} , versus $1.13 \pm 0.12 \text{ mmol}\cdot\text{l}^{-1}$ at t_{30} , and were lower ($p<0.05$) than at baseline.

Table 2

		BASELINE		CREATINE LOADED	
		Before	After	Before	After
15	Insulin ($\text{ng}\cdot\text{ml}^{-1}$)				
	Placebo	0.7 ± 0.1	2.9 ± 0.5	0.7 ± 0.1	3.1 ± 0.7
	Creatine	0.7 ± 0.1	3.0 ± 0.4	0.6 ± 0.1	3.2 ± 0.5
20	Plasma creatine ($\mu\text{mol}\cdot\text{l}^{-1}$)				
	Placebo	47 ± 14	65 ± 18	66 ± 13	78 ± 10
	Creatine	62 ± 20	$1403 \pm 185^*$	$111 \pm 18^*$	$1131 \pm 122^*$

Values are means \pm S.E.M. of 8-9 observations. Insulin, growth hormone (GH), insulin-like-growth-factor 1 (IGF-1) and creatine were measured on venous plasma 30 min before and 30 min after oral glucose ($1 \text{ g glucose}\cdot\text{kg}^{-1} \text{ BW}$) intake in baseline and creatine loaded subjects. Thirty 25 min prior to the glucose administration, subjects ingested 10g of creatine $\cdot\text{H}_2\text{O}$ or placebo.

See Methods for further details. * $p<0.05$ compared to corresponding placebo value.

2.3.2 Blood glucose.

Initial (t_{-30}) blood glucose concentration was 30 similar in both groups ($4.61 - 4.65 \pm 0.1 \text{ mmol}\cdot\text{l}^{-1}$) and was not affected by the acute intake of 10g of creatine monohydrate or placebo in the respective groups, either at baseline or after 12 weeks of creatine ($4.59 \pm 0.2 \text{ mmol}\cdot\text{l}^{-1}$) or placebo ($4.46 \pm 0.2 \text{ mmol}\cdot\text{l}^{-1}$) supplementation.

In P at baseline, ingestion of the oral glucose load ($1\text{g}\cdot\text{kg}^{-1}$) increased blood glucose to a peak value reaching $8.2 \pm 0.4 \text{ mmol}\cdot\text{l}^{-1}$ at t_{30} , where after it returned to $6.7 \pm 0.6 \text{ mmol}\cdot\text{l}^{-1}$ at t_{60} . (Figure 8, panel a). In CR, except at 5 t_{15} , blood glucose concentration following the glucose intake was lower, and peaked at $7.6 \pm 2 \text{ mmol}\cdot\text{l}^{-1}$ at t_{15} , before returning to $5.9 \pm 0.5 \text{ mmol}\cdot\text{l}^{-1}$ by t_{60} . Thus, glucose area (GA) was $154 \pm 21 \text{ mmol}\cdot\text{l}^{-1}\cdot\text{min}$ in P and tended ($p=0.10$) to be lower in CR ($112 \pm 15 \text{ mmol}\cdot\text{l}^{-1}\cdot\text{min}$).

10 At the end of the 12-week supplementation period, the blood glucose response ($\text{GA}=163 \pm 16 \text{ mmol}\cdot\text{l}^{-1}\cdot\text{min}^{-1}$) to glucose ingestion in P was similar to baseline (Figure 8, panel b). However, in CR blood glucose concentrations and glucose area ($90 \pm 22 \text{ mmol}\cdot\text{l}^{-1}\cdot\text{min}^{-1}$) were lower ($p<0.05$).

15 Thus, compared with placebo, creatine supplementation tended to reduce GA following ingestion of the oral glucose load ($p=0.10$).

At baseline, plasma insulin was similar in P and CR (Table 2). Glucose intake obviously increased 20 plasma insulin ($p<0.05$). However, the impact of glucose intake on plasma insulin was independent of acute creatine intake or prior long-term creatine loading.

CLAIMS

1. Use of a creatine compound, in particular creatine or a creatine analogue for the manufacture of a therapeutic preparation for the prevention or treatment of muscle disuse syndrome in a subject.

2. Use as claimed in claim 1, wherein the subject to be treated need not in addition perform a training programme to increase muscle volume and muscle functional capacity.

3. Use as claimed in claim 1 or 2, characterized in that the therapeutic preparation is intended to be administered in an amount that leads to a total daily supplementation of 0,5 to 5 g creatine.

15 4. Use as claimed in claims 1-3, characterized in that the muscle disuse syndrome is the result of immobilization, or reduced level of physical activity due to disease, aging, or (mental or physical) handicap.

20 5. Therapeutic preparation for treating or preventing muscle disuse syndrome, comprising a suitable carrier, diluent or excipient and an effective amount of one or more creatine compounds.

6. Therapeutic preparation according to claim 5, which is a drug.

25 7. Therapeutic preparation according to claim 5, which is a nutritional supplement.

8. Therapeutic preparation according to claim 5 or 7, which has the form of a food stuff comprising one or more additional creatine compounds.

Figure 1




Figure 2





Figure 3







Fig. 4

Figure 5



6/9

Figure 6




Figure 7A




Figure 7B




Figure 7C




Figure 8A





Figure 8B



Rec'd PCT/PTO 20 AUG 2000

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Oral creatine supplementation for treating or preventing
muscle disuse syndrome

the specification of which

(check one)

is attached hereto.

was filed on November 19, 1999 as PCT/EP99/09137 and as
Application Serial No. 09/856,277 received 18 May 2001
and was amended on May 18, 2001
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
98203923.2	Europe	19 November 1998	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Page 2 of 2

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	--

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

William H. Logsdon	22,132	Barbara E. Johnson	31,198	Lester N. Fortney	38,141
Russell D. Orkin	25,363	Paul M. Reznick	33,059	Randall A. Notzen	36,882
David C. Hanson	23,024	John W. McIlvaine	34,219	Jesse A. Hirshman	40,016
Richard L. Byrne	28,498	Michael I. Shamos	30,424	James G. Porcelli	33,757
Frederick B. Ziesenhein	19,438	Blynn L. Shideler	35,034	Kent E. Baldauf, Jr.	36,082
Kent E. Baldauf	25,826	Julie W. Meder	36,216		

Send Correspondence to:

Russell D. Orkin, 700 Koppers Building, 436 Seventh Avenue, Pittsburgh PA 15219-1818

Direct Telephone calls to: (name and telephone number) Russell D. Orkin (412) 471-8815

Full name of sole or first inventor <u>HESPEL Peter Jozef Leo</u>	Inventor's signature 	Date <u>3 July 2001</u>
Residence <u>OUD-HEVERLEE</u>	Belgium	<u>BEX</u>
Citizenship <u>Belgium</u>		
Post Office Address <u>Ophemstraat 103, B-3050 OUD-HEVERLEE, Belgium</u>		
Full name of second joint inventor, if any		
Second inventor's signature		Date
Residence		
Citizenship		
Post Office Address		

(Supply similar information and signature for third and subsequent joint inventors.)